Trial Profile

A Phase 3 study of rilzabrutinib in patients with (CSU) chronic spontaneous urticaria

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilzabrutinib (Primary)
Indications Chronic urticaria
Focus Therapeutic Use

Most Recent Events

25 Apr 2024 According to a Sanofi media release, company is on track to start this trial in H2 2024.
27 Feb 2024 New trial record
24 Feb 2024 According to a Sanofi media release, results from a phase 2 study of rilzabrutinib forms the basis for Phase 3 CSU and prurigo nodularis program to start in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com